A human trial analyzing patients on Semaglutide injections that shows patients who stopped at lower doses of GLP-1 medications experienced less side effects
This stark difference underscores why insurance navigation and patient assistance applications are critical for patients without commercial coverage
Going into GLP-1 therapy with the assumption that weight loss is the only path to happiness is likely to be a setup for disappointment, she says
Theres a lot of research happening now to see how GLP-1 receptor agonists may impact a range of health conditions
The advisory specifically prohibits surrogate advertising disguised as disease awareness campaigns, including billboards at shopping centers, pharmacy signboards advertising availability, social media influencer endorsements, and digital campaigns that create brand recall for prescription products
Phase 3 TRIUMPH-4 results (68 weeks): 9mg dose: 26.4% average weight loss (29.1 kg) 12mg dose: 28.7% average weight loss (32.3 kg) Placebo: 2.1% average weight loss The 12mg retatrutide group lost an average of 71.2 pounds
